References
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy — I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106
Roth GJ, Calverley DC. Aspirin, platelets, and thrombosis: theory and practice. Blood 1994; 83: 885–98
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–60
Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296: 320–31
Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets — I: acetylation of a paniculate fraction protein. J Clin Invest 1975; 56: 624–32
Roth GJ, Siok CJ. Acetylation of the NH2-terminal serine of prostaglandin synthetase by aspirin. J Biol Chem 1978; 253: 3782–4
Marcus AJ, Weksler BB, Jaffe EA. Enzymatic conversion of prostaglandin endoperoxide H2 and arachidonic acid to prostacyclin by cultured human endothelial cells. J Biol Chem 1978; 253: 7138–41
Czervionke RL, Smith JB, Fry GL, et al. Inhibition of prostacyclin by treatment of endothelium with aspirin. J Clin Invest 1979; 63: 1089–92
Fitzgerald DJ, Catella F, Roy L, et al. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988; 77: 142–50
Becker RC, Gore JM. Adjuvant antiplatelet strategies in coronary thrombolysis. Circulation 1991; 87: 1115–7
Roux S, Christeller S, Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischaemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 1992; 19: 671–7
Grines CL. Thrombolytic, antiplatelet, and antithrombotic agents. Am J Cardiol 1992; 70: 18–26
Norris RM, White HD, Cross DB, et al. Aspirin does not improve early arterial patency after streptokinase treatment for acute myocardial infarction. Br Heart J 1993; 69: 492–5
Meijer A, Freek WA, Verheugt MD, et al. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Circulation 1993; 87: 1524–30
Sils D, Rodgers SE, Lloyd JV, et al. Inhibition of platelet aggregation and thromboxane production by low concentrations of aspirin in vitro. Clin Sci 1988; 74: 491–7
Wilson KM, Siebert DM, Duncan EM, et al. Effect of aspirin infusions on platelet function in humans. Clin Sci 1990; 79: 37–42
Bochner F, Williams DB, Morris PMA, et al. Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. Eur J Clin Pharmacol 1988; 35: 287–94
Rowland M, Riegelman S, Harris PA, et al. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci 1972; 61: 379–85
Siebert DJ, Bochner F, Imhoff DM, et al. Aspirin kinetics and platelet aggregation in man. Clin Pharmacol Ther 1983; 33: 367–74
Ross-Lee LM, Elms MJ, Cham BE, et al. Plasma levels of aspirin following effervescent and enteric coated tablets, and their effect on platelet function. Eur J Clin Pharmacol 1982; 23: 545–51
Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. N Engl J Med 1984; 311: 1206–11
Bochner F, Somogyi AA, Wilson KM. Bioinequivalence of four l00mg oral aspirin formulations in healthy volunteers. Clin Pharmacokinet 1991; 21: 394–9
Jiminez AJ, Stubbs ME, Toiler GH, et al. Rapidity and duration of platelet suppression by enteric-coated aspirin in healthy young men. Am J Cardiol 1992; 69: 258–62
Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366–72
Vanags D, Rodgers SE, Lloyd JV, et al. The antiplatelet effect of daily low dose enteric-coated aspirin in man: a time course of onset and recovery. Thromb Res 1990; 59: 995–1005
Zhang CL, Wilson KM, Stafford I, et al. Absorption kinetics of low dose aspirin in patients with evolving acute myocardial infarction. Drug Invest 1994; 7: 169–74
Gibaldi M. Biopharmaceutics and clinical pharmacokinetics. 4th ed. Philadelphia: Lea & Febiger, 1991: 31
Hoffman W, Forster W Two year Cottbus reinfarction study with 30 mg aspirin per day. Prostaglandins Leukot Essent Fatty Acids 1991; 44: 159–69
The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–30
Husted SE, Kraemmer Nielsen H, Krussell LR, et al. Acetylsalicylic acid 100 mg and 1000 mg daily in acute myocardial infarction suspects: a placebo-controlled trial. J Intern Med 1989; 226: 303–10
Verheugt FWA, van de Laarse A, Funke-Kupper AJ, et al. Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. Am J Cardiol 1990; 66: 267–70
Ali M, McDonald JWD, Thiessen N, et al. Plasma acetylsalicylate and salicylate and platelet cyclooxygenase activity following plain and enteric-coated aspirin. Stroke 1980; 11: 9–13
Bochner F, Lloyd JV. Is there an optimal dose and formulation of aspirin to prevent arterial thrombo-embolism in man? Clin Sci 1986; 71: 625–31
Willard JE, Lange RA, Hillis LD. The use of aspirin in ischemic heart disease. N Engl J Med 1992; 327: 175–81
Hirsh J, Dalen JE, Fuster V, et al. Aspirin and other platelet-active drugs: the relationship between dose, effectiveness and side effects. Chest 1992; 102 Suppl. 4: 327S–36S
Jakubowski JA, Stampfer MJ, Vaillancourt R, et al. Low-dose enteric-coated aspirin: a practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase. J Lab Clin Med 1986; 108: 616–21
Clarke RJ, Mayo G, Price P, et al. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325: 1137–41
Bochner F, Siebert DM, Rodgers SE, et al. Measurement of aspirin concentrations in portal and systemic blood in pigs: effect on platelet aggregation, thromboxane and prostacyclin production. Thromb Haemost 1989; 61: 211–6
Di Minno G, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 1983; 61: 1081–5
ACC/AHA Task Force Report. Guidelines for the early management of patients with acute myocardial infarction. J Am Coll Cardiol 1990; 16: 249–92
Ridker PM, Herbert PR, Fuster V, et al. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction? Lancet 1993; 341: 1574–7
Wyllie HR, Dunn FG. Pre-hospital opiate and aspirin administration in patients with suspected myocardial infarction. BMJ 1994; 308: 760–1
Basinski A, Naylor CD. Aspirin and fibrinolysis. Lancet 1988; 2: 1188–9
Basinski A, Naylor CD. Aspirin and fibrinolysis in acute myocardial infarction: meta-analytic evidence for synergy. J Clin Epidemiol 1991; 44: 1085–96
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bochner, F., Lloyd, J.V. Aspirin for Myocardial Infarction. Clin. Pharmacokinet. 28, 433–438 (1995). https://doi.org/10.2165/00003088-199528060-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199528060-00001